JP2024525206A - 上皮成長因子受容体阻害剤の医薬組成物 - Google Patents

上皮成長因子受容体阻害剤の医薬組成物 Download PDF

Info

Publication number
JP2024525206A
JP2024525206A JP2023579156A JP2023579156A JP2024525206A JP 2024525206 A JP2024525206 A JP 2024525206A JP 2023579156 A JP2023579156 A JP 2023579156A JP 2023579156 A JP2023579156 A JP 2023579156A JP 2024525206 A JP2024525206 A JP 2024525206A
Authority
JP
Japan
Prior art keywords
composition
weight
oral dosage
dosage form
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525206A5 (cg-RX-API-DMAC7.html
Inventor
キンキマ,ケイトリン・エヌ
マザイク,デブラ・エル
メデンドープ,クレア・オーブリー
バゼ,オンカー・シュリパッド
Original Assignee
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2024525206A publication Critical patent/JP2024525206A/ja
Publication of JP2024525206A5 publication Critical patent/JP2024525206A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023579156A 2021-06-23 2022-06-22 上皮成長因子受容体阻害剤の医薬組成物 Pending JP2024525206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214099P 2021-06-23 2021-06-23
US63/214,099 2021-06-23
PCT/US2022/034433 WO2022271765A1 (en) 2021-06-23 2022-06-22 Pharmaceutical compositions of an epidermal growth factor receptor inhibitor

Publications (2)

Publication Number Publication Date
JP2024525206A true JP2024525206A (ja) 2024-07-10
JP2024525206A5 JP2024525206A5 (cg-RX-API-DMAC7.html) 2025-06-30

Family

ID=82608194

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579156A Pending JP2024525206A (ja) 2021-06-23 2022-06-22 上皮成長因子受容体阻害剤の医薬組成物

Country Status (9)

Country Link
US (1) US20240293323A1 (cg-RX-API-DMAC7.html)
EP (1) EP4358942A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525206A (cg-RX-API-DMAC7.html)
CN (1) CN117835970A (cg-RX-API-DMAC7.html)
AR (1) AR126195A1 (cg-RX-API-DMAC7.html)
CA (1) CA3223889A1 (cg-RX-API-DMAC7.html)
IL (1) IL309447A (cg-RX-API-DMAC7.html)
TW (1) TW202317120A (cg-RX-API-DMAC7.html)
WO (1) WO2022271765A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523506A (ja) * 2021-06-23 2024-06-28 ブループリント メディシンズ コーポレイション 上皮成長因子受容体阻害剤の塩及び結晶形態
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂
WO2024249660A1 (en) * 2023-05-31 2024-12-05 Amgen Inc. Compositions comprising sotorasib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
US20180064715A1 (en) * 2016-09-07 2018-03-08 Celgene Corporation Tablet compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
JP2024523506A (ja) * 2021-06-23 2024-06-28 ブループリント メディシンズ コーポレイション 上皮成長因子受容体阻害剤の塩及び結晶形態

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
US20180064715A1 (en) * 2016-09-07 2018-03-08 Celgene Corporation Tablet compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCEL GUNTHER, ET AL.: ""Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C7", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 55, no. 36, JPN6026025216, 2016, pages 10890 - 10894, ISSN: 0005887871 *
S.S. SCHALM, ET AL.: ""1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790", ANNALS OF ONCOLOGY, vol. Vol.31, Supplement.4, JPN6026025217, 2020, pages 839, ISSN: 0005887872 *

Also Published As

Publication number Publication date
WO2022271765A1 (en) 2022-12-29
TW202317120A (zh) 2023-05-01
EP4358942A1 (en) 2024-05-01
CN117835970A (zh) 2024-04-05
CA3223889A1 (en) 2022-12-29
US20240293323A1 (en) 2024-09-05
IL309447A (en) 2024-02-01
AR126195A1 (es) 2023-09-27

Similar Documents

Publication Publication Date Title
KR102336378B1 (ko) Azd9291을 포함하는 제약 조성물
KR101737250B1 (ko) 개선된 생체이용률을 갖는 약학 조성물
US20240293323A1 (en) Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
US20230203009A1 (en) Pralsetinib pharmaceutical compositions
KR20230054394A (ko) 비정질 형태의 malt1 억제제 및 이의 제형
EP3860605A1 (en) Crystalline forms and processes of lenvatinib besylate
KR20250002779A (ko) Glp1 정제 조성물
TWI923262B (zh) 7-[4-(4-苯并[b]噻吩-4-基-哌-1-基)丁氧基]-1H-喹啉-2-酮之鹽及具有與該鹽共通之離子之添加劑用於製造控釋性經口固體醫藥組合物之用途
KR20260029301A (ko) 골수성 키놈 억제제의 고체 분산물 및 그를 포함하는 제약 조성물
ES2929730T3 (es) Dispersión sólida
KR101282847B1 (ko) 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물
EP3860606A1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
WO2006040779A2 (en) Controlled release gastric floating matrix formulation containing imatinib
ES2963886T3 (es) Comprimidos que contienen tamsulosina y solifenacina
CN113491695A (zh) 一种仑伐替尼药物组合物、其制备方法及应用
KR101068475B1 (ko) 실로스타졸을 포함하는 서방성 제제 및 이의 제조방법
HK40104279A (en) Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
JP6739275B2 (ja) ゲフィチニブを有効成分とする医薬組成物
RU2857663C2 (ru) Фармацевтическая композиция, содержащая пимитеспиб
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
TW202404585A (zh) 含有匹密特匹(Pimitespib)之醫藥組合物
WO2007147873A1 (en) Oral pharmaceutical composition of a poorly water-soluble active substance
HK1225655B (en) Pharmaceutical compositions comprising azd9291
HK1228245B (en) Pharmaceutical compositions comprising azd9291

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260617